160 Health and Mingyi Zhudao Announce Strategic Partnership Highlighting Open Platform Strategy

On January 14, JiuYi 160 and Mingyi Zhudao signed an agreement in Beijing, establishing a strategic partnership to facilitate resource sharing and leverage complementary strengths. Luo Ningzheng, CEO of JiuYi 160, and Su Shu, CEO of Mingyi Zhudao, attended the signing ceremony.

Mingyi Zhudao is China’s largest mobile surgical platform, enabling patients in need of surgery to promptly book appointments with renowned specialists nationwide and arrange hospital admissions for procedures. Jiuyi 160 is a platform for appointment registration, patient navigation, consultation, and reviews, and it is also the first mobile health company listed on China’s New Third Board (NEEQ).

Through a strategic alliance between Mingyi Zhudao and Jiuyi 160, it has become possible to provide surgical patients with end-to-end services—from consultation guidance, appointment registration, mobile ticket retrieval, in-clinic payment, and booking renowned specialists, to post-consultation reviews—all of which are available on the platform.

When discussing the original intention behind the collaboration between the two parties, Su Shu stated that through cooperation, the two companies can achieve complementary advantages, enabling comprehensive integration of their medical resources and patient services. This will better enhance the efficiency of the healthcare system and improve patients' experience in seeking medical care, ultimately achieving a win-win situation for all parties involved.

From the perspective of JiuYi160, this collaboration also exemplifies its strategic objectives for 2016: to break down traditional barriers in medical information through three core strategies—connectivity, openness, and ecosystem building—by creating a platform that connects hospitals, physicians, and patients, thereby fostering an open and mutually beneficial ecosystem in the healthcare sector.

According to Luo Ningzheng, the open platform strategy of Jiuyi 160 was launched earlier and has already achieved remarkable results. Last year, Jiuyi 160 carried out in-depth cooperation with major high-traffic platforms such as BAT, Sina, 360, and Sogou in areas including search, appointment registration, consultation, additional appointment slots, personal health records, and private doctors.

In addition, JiuYi 160 has engaged in extensive and in-depth collaborations with multiple cross-industry brands, including Shenzhen Boai Group, Ciming Health Checkup, Kangmei Pharmaceutical, Min’an Insurance, and Fosun, across areas such as brand promotion, experience services, appointment registration, insurance products, and high-end health management.

Jiuyi160 will also collaborate with authoritative medical institutions in the United States, Japan, and South Korea to launch cross-border medical services, catering to diverse healthcare needs. Featured offerings include consultations and treatment for critical illnesses in the U.S., premium health checkups and cancer screening in Japan, and cosmetic surgery in South Korea, along with a variety of other health and medical programs available in the U.S. and Japan. Through the Jiuyi160 website, users can book appointments with multiple accredited overseas medical institutions.

In the future, JiuYi160 aims to build a new “Internet+ Healthcare” ecosystem on the basis of its open platform, incorporating elements such as overseas medical services, insurance institutions, pharmaceutical manufacturers, chronic disease management, health management, medical experience, and hardware manufacturers. Currently, large organizations such as Kangmei Pharmaceutical and Ping An Insurance have established strategic partnerships with JiuYi160, hoping to collaborate in building a vast “Internet+ Healthcare” ecosystem.

It is reported that since its listing, Jiuyi 160 has received private placement intentions from several top-tier funds. It is foreseeable that Jiuyi 160 will undertake a series of initiatives in the capital market and industry layout over the coming year. VCBeat will continue to closely monitor the development of Jiuyi 160’s open platform strategy.